Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)


Section Navigation
			
			CDC Home








National TB Program Objectives and Performance Targets for 2025										Related Pages
										**The mission of the Division of Tuberculosis Elimination is to promote health and quality of life by preventing, controlling, and eventually eliminating tuberculosis (TB) from the United States, and by collaborating with other countries and international partners in controlling global tuberculosis.**
The mission of the Division of Tuberculosis Elimination is to promote health and quality of life by preventing, controlling, and eventually eliminating tuberculosis (TB) from the United States, and by collaborating with other countries and international partners in controlling global tuberculosis.
Objectives for Reducing TB Incidence**1,2,3,4**
**Targets**TB Incidence
Reduce the incidence of TB disease.
1.3 cases per 100,000US-Born Persons
Decrease the incidence of TB disease among US-born persons.
0.4 cases per 100,000Non-US–Born Persons
Decrease the incidence of TB disease among non-US–born persons.
8.8 cases per 100,000US-Born Non-Hispanic Blacks or African Americans
Decrease the incidence of TB disease among US-born non-Hispanic blacks or African Americans.
1.0 cases per 100,000Children Younger than 5  Years of Age
Decrease the incidence of TB disease among children younger than 5 years of age.
0.1 cases per 100,000Objectives on Case Management and Treatment**1,2,3**
**Targets**Known HIV Status
Increase the proportion of TB patients with a positive or negative HIV test result reported.
99%Treatment Initiation
For TB patients with positive acid-fast bacillus (AFB) sputum-smear results, increase the proportion who initiated treatment within 7 days of specimen collection.
96%Recommended Initial Therapy
For patients whose diagnosis is likely to be TB disease, increase the proportion who  start on the recommended initial 4-drug regimen.
97%Sputum Culture Result Reported
For TB patients aged 12 years or older with a pleural or respiratory site of disease, increase the proportion who have a sputum culture result reported.
99%Sputum Culture Conversion
For TB patients with positive sputum culture results, increase the proportion with a documented conversion to negative results within 60 days of treatment initiation.
83%Completion of Treatment
For patients with newly diagnosed TB disease for whom 12 months or less of treatment is indicated, increase the proportion who complete treatment within 12 months.
95%Objectives on Laboratory Reporting**1,2,3**
**Targets**Turnaround Time — Culture
For TB patients with cultures of respiratory specimens identified with *M. tuberculosis* complex (MTBC), increase the proportion reported by the laboratory within 25 days from the date the specimen was collected.
**NOTE:***25 days includes 21 days for culture to grow and 4 days for specimen collection and delivery to lab.*
78%Turnaround Time — Nucleic Acid Amplification Test (NAAT)
For TB patients with respiratory specimens positive for MTBC by nucleic acid amplification test (NAAT), increase the proportion reported by the laboratory within 6 days from the date the specimen was collected.
**NOTE:** *6 days includes 2 days for detection and 4 days for specimen collection and delivery to lab.*
97%Drug-Susceptibility Result5
For TB patients with positive culture results, increase the proportion who have initial drug-susceptibility results reported.
100%Universal Genotyping
For TB patients with a positive culture result, increase the proportion who have a MTBC genotyping result reported.
100%Objectives on Contact Investigations**1,3,6**
**Targets**Contact Elicitation
For TB patients with positive AFB sputum-smear results, increase the proportion who have contacts elicited.
100%Examination
For contacts to sputum AFB smear-positive TB cases, increase the proportion who are examined for infection and disease.
94%Treatment Initiation
For contacts to sputum AFB smear-positive TB cases diagnosed with latent TB infection, increase the proportion who start treatment.
92%Treatment Completion
For contacts to sputum AFB smear-positive TB cases who have started treatment for latent TB infection, increase the proportion who complete treatment.
93%Objectives on Examination of Immigrants and Refugees**1,3,7**
**Targets**Examination Initiation
For immigrants and refugees with abnormal chest radiographs (X-rays) read overseas as consistent with TB, increase the proportion who initiate a medical examination within 30 days of notification.
72%Examination Completion
For immigrants and refugees with abnormal chest X-rays read overseas as consistent with TB, increase the proportion who complete a medical examination within 120 days of notification.
78%Treatment Initiation
For immigrants and refugees with abnormal chest X-rays read overseas as consistent with TB who are diagnosed with latent TB infection or have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the United States, for whom treatment was recommended, increase the proportion who start treatment.
87%Treatment Completion
For immigrants and refugees with abnormal chest X-rays read overseas as consistent with TB who are diagnosed with latent TB infection or have radiographic findings consistent with prior pulmonary TB (ATS/CDC Class 4) on the basis of examination in the United States, and who have started on treatment, increase the proportion who complete treatment.
87%Objectives on Data Reporting
**Targets**RVCT8
Ensure the completeness of each core Report of Verified Case of Tuberculosis (RVCT) data item reported to CDC.
100%ARPE9
Ensure the completeness of each core Aggregate Reports for Tuberculosis Program Evaluation (ARPE) data items reported to CDC.
100%EDN10
Ensure the completeness of each core TB Follow-Up Worksheet data item reported to CDC via the Electronic Disease Notification (EDN) system.
93%Objectives on Program EvaluationEvaluation Activities
Ensure submission of a program-specific performance-monitoring plan and an annual program evaluation plan to improve program performance.
100%Evaluation Focal Point
Ensure designation of a TB evaluation focal point.
100%Objectives on Human Resource DevelopmentDevelopment Plan
Ensure submission of a program-specific human resource development plan (HRD) and a yearly update of progress.
100%Training Focal Point
Ensure designation of a TB training focal point.
100%
Footnotes:
Indicator calculations for measuring progress are established by the National TB Indicators Project (NTIP).
Targets for incidence rates and objectives on case management and laboratory reporting are established on the basis of performance reported in NTIP using 2010–2018 data from the National TB surveillance system. For Sputum Culture Conversion and Completion of Treatment, the latest year with data available is 2017.
Targets are based on a statistical model that uses data to find trends from 2010 through 2018 (or the latest year with data available). TB programs with fewer than 150 cases from 2016–2018 were excluded. For each objective, we used a quantile regression model to estimate the 90th percentile for each year, and extrapolated the fitted model to predict the estimated 90th percentile in the year 2025, which served as the target for 2025. The “90th percentile” values reflect the projected performance of the top 10% of TB programs in the United States in 2025. The quantile regression serves to establish a smooth trend over time, which is useful since the actual percentiles in any given year (e.g. the final year of available data) may not be representative of the overall trend.
Population data are derived from the American Community Survey. Jurisdictions with a non-US–born population or US-born non-Hispanic black or African American population less than an average of 100,000 persons per year in 2015–2017 are also excluded in the statistical model for TB incidence rates for non-US–born persons and US-born non-Hispanic blacks or African Americans.
Drug-susceptibility results from molecular tests will be counted as having met the objective in the indicator calculation starting in 2020.
Targets for objectives on contact investigation are established on the basis of performance reported in NTIP using 2010–2016 data from the Aggregate Reports for Tuberculosis Program Evaluation (ARPE) for contacts.
Targets for objectives on the examination of immigrants and refugees are established on the basis of performance reported in NTIP using 2010–2018 data from the Electronic Disease Notification (EDN) system. For Treatment Initiation and Treatment Completion, the latest year with data available is 2017.
Report of Verified Case of Tuberculosis (RVCT) is the standard surveillance data collection form for reporting tuberculosis cases.
Aggregate Reports for Tuberculosis Program Evaluation (ARPE) is the standard form for reporting contact investigation activities.
Electronic Disease Notification (EDN) system is a web-based system used to notify health departments of the immigrants and refugees’ entry into the United States. The system also includes a module for the TB Follow-Up Worksheet, a data collection form for reporting the outcomes of TB follow-up examinations in the United States.Related LinksMonitoring Tuberculosis Programs *MMWR* 2010; 59 (No.10); 295-298
National TB Indicators Project (NTIP) – Fact sheet
National TB Indicators: 2013 State Comparison
							
					
							Last Reviewed:  October 21, 2022						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue